141 related articles for article (PubMed ID: 33998827)
1. Qualitative Assessment of Advanced MRI in Post-Treatment High Grade Gliomas Follow Up: Do We Agree?
Zakhari N; Taccone M; Torres C; Chakraborty S; Sinclair J; Woulfe J; Jansen G; Cron G; Nguyen TB
Can Assoc Radiol J; 2022 Feb; 73(1):187-193. PubMed ID: 33998827
[TBL] [Abstract][Full Text] [Related]
2. Prospective comparative diagnostic accuracy evaluation of dynamic contrast-enhanced (DCE) vs. dynamic susceptibility contrast (DSC) MR perfusion in differentiating tumor recurrence from radiation necrosis in treated high-grade gliomas.
Zakhari N; Taccone MS; Torres CH; Chakraborty S; Sinclair J; Woulfe J; Jansen GH; Cron GO; Thornhill RE; McInnes MDF; Nguyen TB
J Magn Reson Imaging; 2019 Aug; 50(2):573-582. PubMed ID: 30614146
[TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
[TBL] [Abstract][Full Text] [Related]
4. Textural features of dynamic contrast-enhanced MRI derived model-free and model-based parameter maps in glioma grading.
Xie T; Chen X; Fang J; Kang H; Xue W; Tong H; Cao P; Wang S; Yang Y; Zhang W
J Magn Reson Imaging; 2018 Apr; 47(4):1099-1111. PubMed ID: 28845594
[TBL] [Abstract][Full Text] [Related]
5. Arterial Spin-Labeling and DSC Perfusion Metrics Improve Agreement in Neuroradiologists' Clinical Interpretations of Posttreatment High-Grade Glioma Surveillance MR Imaging-An Institutional Experience.
Yamin G; Tranvinh E; Lanzman BA; Tong E; Hashmi SS; Patel CB; Iv M
AJNR Am J Neuroradiol; 2024 Apr; 45(4):453-460. PubMed ID: 38453410
[TBL] [Abstract][Full Text] [Related]
6. Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis.
Murayama K; Nishiyama Y; Hirose Y; Abe M; Ohyu S; Ninomiya A; Fukuba T; Katada K; Toyama H
Magn Reson Med Sci; 2018 Jan; 17(1):42-49. PubMed ID: 28515410
[TBL] [Abstract][Full Text] [Related]
7. Combining Diffusion Tensor Metrics and DSC Perfusion Imaging: Can It Improve the Diagnostic Accuracy in Differentiating Tumefactive Demyelination from High-Grade Glioma?
Hiremath SB; Muraleedharan A; Kumar S; Nagesh C; Kesavadas C; Abraham M; Kapilamoorthy TR; Thomas B
AJNR Am J Neuroradiol; 2017 Apr; 38(4):685-690. PubMed ID: 28209583
[TBL] [Abstract][Full Text] [Related]
8. Brain Gliomas: Multicenter Standardized Assessment of Dynamic Contrast-enhanced and Dynamic Susceptibility Contrast MR Images.
Anzalone N; Castellano A; Cadioli M; Conte GM; Cuccarini V; Bizzi A; Grimaldi M; Costa A; Grillea G; Vitali P; Aquino D; Terreni MR; Torri V; Erickson BJ; Caulo M
Radiology; 2018 Jun; 287(3):933-943. PubMed ID: 29361245
[TBL] [Abstract][Full Text] [Related]
9. Correlation of Tumor Immunohistochemistry with Dynamic Contrast-Enhanced and DSC-MRI Parameters in Patients with Gliomas.
Nguyen TB; Cron GO; Bezzina K; Perdrizet K; Torres CH; Chakraborty S; Woulfe J; Jansen GH; Thornhill RE; Zanette B; Cameron IG
AJNR Am J Neuroradiol; 2016 Dec; 37(12):2217-2223. PubMed ID: 27585700
[TBL] [Abstract][Full Text] [Related]
10. Glioma grading capability: comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI.
Choi HS; Kim AH; Ahn SS; Shin NY; Kim J; Lee SK
Korean J Radiol; 2013; 14(3):487-92. PubMed ID: 23690718
[TBL] [Abstract][Full Text] [Related]
11. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?
Weber MA; Henze M; Tüttenberg J; Stieltjes B; Meissner M; Zimmer F; Burkholder I; Kroll A; Combs SE; Vogt-Schaden M; Giesel FL; Zoubaa S; Haberkorn U; Kauczor HU; Essig M
Invest Radiol; 2010 Dec; 45(12):755-68. PubMed ID: 20829706
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Values of DCE-MRI and DSC-MRI for Differentiation Between High-grade and Low-grade Gliomas: A Comprehensive Meta-analysis.
Liang J; Liu D; Gao P; Zhang D; Chen H; Shi C; Luo L
Acad Radiol; 2018 Mar; 25(3):338-348. PubMed ID: 29223713
[TBL] [Abstract][Full Text] [Related]
13. Reproducibility of dynamic contrast-enhanced MRI and dynamic susceptibility contrast MRI in the study of brain gliomas: a comparison of data obtained using different commercial software.
Conte GM; Castellano A; Altabella L; Iadanza A; Cadioli M; Falini A; Anzalone N
Radiol Med; 2017 Apr; 122(4):294-302. PubMed ID: 28070841
[TBL] [Abstract][Full Text] [Related]
14. Simplified perfusion fraction from diffusion-weighted imaging in preoperative prediction of IDH1 mutation in WHO grade II-III gliomas: comparison with dynamic contrast-enhanced and intravoxel incoherent motion MRI.
Wang X; Cao M; Chen H; Ge J; Suo S; Zhou Y
Radiol Oncol; 2020 Jun; 54(3):301-310. PubMed ID: 32559177
[TBL] [Abstract][Full Text] [Related]
15. Differential diagnosis of central lymphoma and high-grade glioma: dynamic contrast-enhanced histogram.
Zhang HW; Lyu GW; He WJ; Lei Y; Lin F; Feng YN; Wang MZ
Acta Radiol; 2020 Sep; 61(9):1221-1227. PubMed ID: 31902220
[TBL] [Abstract][Full Text] [Related]
16. Dynamic susceptibility contrast and dynamic contrast-enhanced MRI characteristics to distinguish microcystic meningiomas from traditional Grade I meningiomas and high-grade gliomas.
Hussain NS; Moisi MD; Keogh B; McCullough BJ; Rostad S; Newell D; Gwinn R; Foltz G; Mayberg M; Aguedan B; Good V; Fouke SJ
J Neurosurg; 2017 Apr; 126(4):1220-1226. PubMed ID: 27285539
[TBL] [Abstract][Full Text] [Related]
17. Evaluating feasibility of high resolution T1-perfusion MRI with whole brain coverage using compressed SENSE: Application to glioma grading.
Sasi S D; Ramaniharan AK; Bhattacharjee R; Gupta RK; Saha I; Van Cauteren M; Shah T; Gopalakrishnan K; Gupta A; Singh A
Eur J Radiol; 2020 Aug; 129():109049. PubMed ID: 32464580
[TBL] [Abstract][Full Text] [Related]
18. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects.
Fink JR; Carr RB; Matsusue E; Iyer RS; Rockhill JK; Haynor DR; Maravilla KR
J Magn Reson Imaging; 2012 Jan; 35(1):56-63. PubMed ID: 22002882
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric evaluation of low grade gliomas at follow-up: comparison between diffusion and perfusion MR with (18)F-FDOPA PET.
Rossi Espagnet MC; Romano A; Mancuso V; Cicone F; Napolitano A; Scaringi C; Minniti G; Bozzao A
Br J Radiol; 2016 Oct; 89(1066):20160476. PubMed ID: 27505026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
